Business Context and Reporting Period
Company: GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.)
Reporting Period: Fiscal Year Ended December 31, 2025
Trading Symbol: GRDX (Nasdaq Capital Market)
Business Transformation: The Company underwent a material strategic pivot in 2025. It acquired Grid AI Corp. (including a 75% interest in AMPX) on September 30, 2025, shifting focus to AI-driven energy orchestration for data centers. Simultaneously, it completed a rescission transaction on December 31, 2025, unwinding its prior acquisition of ImmunogenX (IMGX) and retaining only the legacy Adrulipase biopharmaceutical program.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $36,251 | $0 |
| Net Loss | $(6,553,578) | $(18,059,336) |
| Loss from Continuing Operations | $(6,241,280) | $(15,619,021) |
| Loss from Discontinued Operations | $(312,298) | $(2,440,315) |
| Cash and Cash Equivalents (Year-End) | $899,784 | $163,476 |
| Working Capital Deficit | $(12,563,000) | $(24,587,316) |
| Accumulated Deficit | $(208,780,662) | $(202,388,008) |
| Operating Cash Flow | $(5,702,824) | $(9,217,823) |
Note: 2025 revenue is derived entirely from the Grid AI segment post-acquisition. The 2024 results included the IMGX business, which was classified as discontinued operations in 2025.
Material Changes vs. Prior Period
- Revenue Generation: The Company moved from zero revenue in 2024 to $36,251 in 2025, driven by the Grid AI acquisition. However, this resulted in a gross loss of $(657,432) due to high initial service costs.
- Expense Reduction: Total operating expenses decreased by approximately $9.2 million (59%) year-over-year, primarily due to the removal of IMGX-related transaction costs and the discontinuation of several legacy biopharmaceutical programs (Capeserod, Niclosamide, Latiglutenase, CypCel).
- Asset Restructuring: The Company derecognized approximately $83.2 million in assets and $23.7 million in liabilities associated with the IMGX rescission. Conversely, it recognized $22.4 million in goodwill and $22.4 million in intangible assets from the Grid AI acquisition.
- Debt Status: The Company entered a Revolving Loan Agreement in January 2025. As of the filing date, the Company is in default on this facility, with a demand for repayment of approximately $1.0 million issued in April 2026.
Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance due to recurring losses, negative cash flows, and the debt default. The financial statements do not include adjustments that might result from this uncertainty.
- Nasdaq Compliance: The Company received a notice from Nasdaq on April 22, 2026, regarding non-compliance with listing rules due to the failure to timely file its 2025 10-K. It has 60 days to submit a compliance plan.
- Strategic Focus: The Grid AI segment is in the development stage with no major customers yet. The AI data center platform has not been commercially deployed. The legacy Adrulipase program remains in clinical development but has no active trials as of year-end.
- Legal Contingencies: The Company is negotiating a settlement with Ellenoff Grossman & Schole LLP regarding unpaid legal fees, with a proposed resolution in the range of $400,000. No liability has been recorded as a loss is not deemed probable.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to the integration of Grid AI Corp., citing insufficient accounting resources and processes.
Investor Verification Checklist
- Debt Default Resolution: Verify the status of negotiations with the lender regarding the $1.0 million demand for repayment under the Revolving Loan Agreement.
- Nasdaq Listing Status: Confirm whether the Company has submitted a compliance plan to Nasdaq and the likelihood of regaining compliance to avoid delisting.
- Liquidity Runway: Assess the sufficiency of the $0.9 million cash balance against operating burn rates and the immediate debt obligation.
- Grid AI Commercialization: Investigate the progress of the AI data center platform, specifically the status of the potential customer deployment mentioned in the filing.
- Equity Dilution: Review the terms of the Series H Preferred Stock (38.8 million shares convertible) and recent subsequent equity issuances to understand potential dilution.